Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine is part of Highly Active Antiretroviral Therapy (HAART), which can be used to treat human immunodeficiency virus (HIV) type 1.
EFdA-TP, a highly potent nucleoside reverse transcriptase (RT) inhibitor, exerts its inhibitory effect on RT-catalyzed DNA synthesis through both immediate and delayed chain termination mechanisms, commonly referred to as ICT and DCT, respectively. Additionally, EFdA-TP demonstrates its efficacy in inhibiting HIV-1 RT through multiple pathways.
EFdA-TP tetraammonium is an influential nucleoside reverse transcriptase (RT) inhibitor that effectively prevents RT-mediated DNA synthesis by acting as an immediate or delayed chain terminator (ICT or DCT). Additionally, EFdA-TP tetraammonium exhibits multiple mechanisms of inhibiting HIV-1 RT[1].
L-696229 is a specific inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). L-696229 inhibited RT activity in a mutually exclusive manner with respect to either phosphonoformate or azidothymidine triphosphate and was a weak
HIV-1 inhibitor-30 (compound 10i) is a potent inhibitor of HIV-1, specifically targeting the RT DNA polymerase enzyme. It exhibits strong antiretroviral activity, with an EC 50 value of 40 nM and an IC 50 value of 80 nM. Furthermore, HIV-1 inhibitor-30 demonstrates significant effectiveness against seven NNRTI-resistant strains of HIV-1 (RT-K103N; RT-Y181C; RT-K103N, Y181C; RT-L100I, K103N; RT-Y188L; RT-K103N, G190A; RT-K103N, V108I), with IC 50 values ranging from 0.04 to 1.42 μM. This compound holds potential for AIDS research [1].